Treatment with Cellgevity® improves glycemic index and prevents atherogenic dyslipidemia in Type 2 Diabetic rat model

Samenvatting

Background: Type 2 Diabetic (T2DM) dependent high rate of coronary failure is attributed to the prevalence of dyslipidemia and other risk factors. The impairment of lipid metabolism in T2DM is linked to chronic oxidative stress; therefore, a rational therapeutic approach in diabetogenic management could involve the use of antioxidants. The current study evaluates the effect of Cellgevity® (a marketed glutathione supplement) on body weight, fasting blood glucose and plasma lipoprotein levels of T2DM male rats. T2DM was achieved via sucrose feeding (60%W/V) ad libitum for 3 weeks and streptozotocin (STZ at 55 mg/kg) intraperitoneal administration on day 22.

Method: Seventy-two hours after STZ injection, twenty one diabetic rats were divided into three groups of 7 rats each. Control and diabetic untreated (DM-untreated) groups received distilled water, diabetic treated 1 group (DM-treated 1) received Cellgevity (25mg/kg) and Diabetic treated 2 (DM-treated 2) group received Cellgevity (40 mg/kg) for twenty one days respectively.

Results: Our results show that Cellgevity significantly (p<0.001) reduced FBG level (40% and 45%) in DM-treated 1 & 2 respectively compared to DM-untreated animals. Serum lipoproteins were significantly distorted in the DM-untreated group compared with the Control group, however, treatment with Cellgevity® in DM-treated 1&2 significantly decrease TG (%), TC (%) and LDL (%) while HDL was significantly increased (%) compared to the DM-untreated group.

Conclusion: Overall, present results show anti-hyperglycemic and anti-dyslipidemic potentials, of Cellgevity in T2DM rats; which might be via oxidative stress modulation.